Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
NCT06402708

Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)

Led by Fudan University · Updated on 2026-04-27

172

Participants Needed

1

Research Sites

316 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to learn the role of adjuvant chemotherapy for patients with thymic carcinoma and completed resection. The main questions it aims to answer are: 1. Does adjuvant chemotherapy decrease disease progression? 2. Does medium dose of three drugs (paclitaxel, cisplatin, 5-FU) well tolerance? Researchers will compare chemoradiotherapy to radiotherapy to see whether chemoradiotherapy could decrease disease progression or not. Participants will: 1. Take radiotherapy (50Gy/25f) with or without 4 cycles of chemotherapy (TPF). 2. Follow up every 3 months in the first two year, and then every 6 months.

CONDITIONS

Official Title

Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Volunteer and sign informed consent
  • Aged 18 to 75 years old
  • Surgery completed within the past 3 months
  • Histologically confirmed thymic cancer
  • Complete tumor removal confirmed by surgery and imaging
  • Masaoka stage I to III disease
  • No severe dysfunction of blood, heart, lung, liver, kidney, or immune system
  • Blood counts and liver/kidney tests within specified normal limits
Not Eligible

You will not qualify if you...

  • Having a second primary tumor, except certain cured or low-risk cancers
  • Symptomatic coronary heart disease, left heart failure, uncontrolled seizures, or loss of consciousness due to mental illness
  • Pregnant or breastfeeding
  • Drug addiction, chronic alcoholism, or AIDS
  • Deemed unsuitable by researchers

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China, 212013

Actively Recruiting

Loading map...

Research Team

X

Xingwen Fa, Doctor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3) | DecenTrialz